Mounjaro and Heart Side Effects: Reading the Evidence Carefully

What large-scale trial data tells us about heart risk on tirzepatide

The SURMOUNT programme, which recruited thousands of adults with obesity across its studies, tracked cardiovascular safety endpoints alongside weight outcomes. In SURMOUNT-1, published in the New England Journal of Medicine, serious cardiac events were not elevated in the tirzepatide groups compared with placebo over 72 weeks. The NICE committee's appraisal of tirzepatide (NICE TA1026, published in December 2024) reviewed this evidence base and did not identify cardiac harm as a concern limiting the medicine's use in eligible adults.

One cardiovascular signal that does appear consistently in the data is a modest increase in resting heart rate: roughly 2–3 beats per minute above baseline at higher doses. For most people this is imperceptible and clinically unimportant. For someone who already has a significant arrhythmia or whose heart rate was already at the upper end of normal, it is something a prescriber will weigh carefully before recommending treatment.

It is also worth noting that tirzepatide carries what is known as a Black Triangle (▼) designation from the MHRA, meaning it is subject to additional post-marketing monitoring. This is standard for newer medicines, it reflects the MHRA's caution, not an unresolved safety crisis. The NHS tirzepatide medicines page summarises the known side-effect profile in plain terms and is a reliable reference if you want a straightforward overview.

Palpitations and heart-rate changes: how common are they, and why do they happen

Among the side effects people actually report to their clinical teams, palpitations sit in the less common category (affecting fewer than one in ten users) rather than the common GI-led cluster of nausea, loose stools and indigestion that occupies most of the early weeks. When palpitations do occur, they are often linked to dehydration from GI illness rather than to a direct effect on the heart muscle itself. Staying well hydrated, particularly during any bout of sickness or diarrhoea, reduces this risk noticeably.

Some people experience a brief awareness of their heartbeat in the first few days after a new dose or a dose increase, the kind of sensation that is more startling than dangerous. It tends to settle as the body adjusts. The full Mounjaro side-effects overview covers this pattern in more detail, including how the titration schedule is designed partly to reduce the intensity of early reactions.

If palpitations are persistent, happen at rest, come with dizziness or chest discomfort, or feel significantly different from anything you have experienced before, that is a conversation to have with a clinician rather than something to observe and wait out. Your GP and, if relevant, our prescribers are the right people to contact first. The contact page explains how to reach the aftercare team if you are already on treatment through us.

When to get medical help: heart-related symptoms that should not wait

This is the section of any medicines information that matters most, so it deserves plain, unambiguous language. Call 999 or go to A&E immediately if you experience: chest pain or tightness that does not resolve quickly; breathlessness at rest or that wakes you from sleep; a very fast, pounding heartbeat with dizziness or fainting; or any of these symptoms together. Do not adjust or stop your dose on your own in an emergency, call for help first.

For symptoms that are uncomfortable but not acute (a racing pulse that settles within a few minutes, occasional awareness of your heartbeat, mild dizziness after injection) contact your prescriber or GP before your next scheduled dose. A short pause in treatment, a slower titration, or simply reassurance after a clinical assessment is often all that is needed. There is no requirement to push through a symptom that genuinely worries you.

The MHRA's Yellow Card reporting tool allows patients to log side effects directly, and those reports actively inform how regulators update guidance over time. If you are unsure whether what you experienced counts, our page on side effects if you are taking Mounjaro can help you decide whether something warrants reporting. If something happens to you on tirzepatide that is not listed in the patient information leaflet, reporting it is a genuine contribution to medicine safety, not an overreaction.

How clinical assessment shapes the picture before treatment starts

None of the above is a reason to avoid treatment if you are otherwise suitable. The cardiovascular story around GLP-1 and dual GIP/GLP-1 medicines is, if anything, moving in an encouraging direction, reduced weight and improved metabolic markers tend to lower longer-term cardiovascular risk in people with obesity-related conditions. The NICE and MHRA review processes take this broader picture into account.

What a thorough clinical assessment does is ensure that any individual contraindications (a significant pre-existing arrhythmia, certain cardiac medications, an resting heart rate already elevated) are identified before treatment begins rather than discovered during it. The tirzepatide heart side effects page explores the mechanism in more depth for readers who want a closer look at the science. It is also reassuring to know that some people tolerate the medicine without any adverse effects at all, and our page on what happens when Mounjaro causes no side effects addresses what that can mean and why it is still working. For those who want a broader grounding in the treatment before committing, our Mounjaro information page covers everything from how tirzepatide works to what the weekly injection schedule looks like in practice. Among the most useful things to read before you begin are the five Mounjaro side effects that come up most often in clinical practice, so you know in advance what to expect and what to act on. For those who are further along in their thinking, the free consultation is where that individual picture is reviewed by a real GPhC-registered prescriber. No algorithm screens your answers, a named clinician reads them. If you are approved, your treatment leaves the same day (orders placed before 12pm, Monday to Friday), and arrives via DPD the next working day in plain, unmarked packaging. Our clinical team is available for aftercare questions seven days a week.